DNA POLYMERASE TECHNOLOGY, INC.
Engineered DNA polymerases optimized for rapid, specific PCR detection with inhibitor tolerance and hot-start performance
- Sector
- Medtech
- Total capital
- $566K
- Federal grants
- $566K
- 2 awards · 2015–2018
- Rank in peer group#14 of 28
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 11 pending · first 2017
- Rank in peer group#1 of 28
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Robust and Fast Taq Mutants Designed for Direct and Rapid Point of Care Tests$150K
- Federal grantHealth and Human S · Phase II · Direct RT-PCR detection of RNA pathogens in crude samples$417K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 28 peers
Line = medianMedtech · Molecule
- Federal grants#14 · top 50%
- Granted patents#1 · top 4%
- Linked publications#3 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 7 granted of 18- GrantedFast And Robust Bi-functional Mutants Of Taq Dna PolymeraseUSPTOUS 12,655,479
- PendingInhibition-resistant PolymerasesUSPTOApplication 19028945
- GrantedInhibition-resistant PolymerasesUSPTOUS 12,305,228
Show all 18 patent records
- Fast And Robust Bi-functional Mutants Of Taq Dna PolymeraseJun 16, 2026 · US 12,655,479Granted
- Inhibition-resistant PolymerasesJun 12, 2025 · Application 19028945Pending
- Inhibition-resistant PolymerasesMay 20, 2025 · US 12,305,228Granted
- Mutant Polymerases And Uses ThereofMar 11, 2025 · US 12,247,230Granted
- Mutant Polymerases And Uses ThereofNov 14, 2023 · US 11,814,655Granted
- Mutant Polymerases And Uses ThereofAug 17, 2021 · US 11,091,745Granted
- Inhibition-resistant PolymerasesJun 16, 2020 · US 10,683,537Granted
- Use Of Taq Polymerase Mutant Enzymes For Nucleic Acid Amplification In The Presence Of Pcr InhibitorsOct 24, 2017 · US 9,796,965Granted
- Mutant Polymerases With Fast Elongating ActivitySep 26, 2013 · Application 13907891Pending
- Use Of Taq Polymerase Mutant Enzymes For Dna Amplification In The Presence Of Pcr InhibitorsApplication PCTUS2007078571Pending
- Fast And Robust Bi-functional Mutants Of Taq Dna PolymeraseApplication 63262382Pending
- Mutant Polymerases And Uses ThereofApplication PCTUS2016032041Pending
- Mutant Polymerases And Uses ThereofApplication 62160404Pending
- Inhibition-resistant PolymerasesApplication PCTUS2013065313Pending
- Inhibition-resistant Dna PolymerasesApplication 61811611Pending
- Inhibition-resistant Dna PolymerasesApplication 61714671Pending
- Composition To Overcome Inhibitors In Pcr And Growth CulturesApplication PCTUS2011067040Pending
- Compositions For Improving Gene AmplificationApplication PCTUS2009066868Pending
Recent research by its founders
- Synergistic adaptation of rice root phosphorus uptake kinetics and leaf carbon–nitrogen metabolism under low-phosphorus conditions20260 cites
- Influence of Dietary Forage Neutral Detergent Fiber on Ruminal Fermentation, Chewing Activity, Nutrient Digestion, and Ruminal Microbiota of Hu Sheep202514 cites
- Response of Photosynthesis and Chlorophyll Fluorescence to Nitrogen Changes in Rice with Different Nitrogen Use Efficiencies20256 cites
Related companies, and why
- BLEEP, LLCSimilar federal contract value in Medtech · null in contracts
- Durin Life Sciences, Inc.Similar federal contract value in Medtech · null in contracts
- SydnexisSimilar federal contract value in Medtech · null in contracts
- CHS Healthcare Ventures, IncSimilar federal contract value in Medtech · null in contracts
- TINYKICKS, INC.Similar federal contract value in Medtech · null in contracts
- Flex Biomedical, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .